Special Issue "Adenosine Receptors as Attractive Targets in Human Diseases"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 30 June 2020.
Interests: medicinal chemistry; drug design; small molecules; heterocyclic compounds; adenosine receptor ligands; glutamate receptor antagonists; protein kinase CK2 inhibitors; carbonic anhydrase inhibitors
Interests: medicinal chemistry; rational drug design; heterocyclic compounds; structure–activity relationships; adenosine receptor ligands; glutamate receptor antagonists; carbonic anhydrase inhibitors; protein kinase CK2 inhibitors
Interests: drug design; heterocyclic compounds; adenosine receptors antagonists; glutamate receptor antagonists; protein kinase CK2 inhibitors; carbonic anhydrase inhibitors
Adenosine is a ubiquitous neuromodulator, both in the central and peripheral nervous systems, and is also present in almost all organs and tissues. It activates G-protein coupled receptors, classified as A1, A2A, A2B and A3 adenosine receptor (AR) subtypes, which have different tissue/organ distribution and effector couplings. Thus, adenosine modulates a wide variety of physiological processes, such as neuronal and cardiovascular activities, immune system functions and cellular metabolism, and it is also implicated in different pathological conditions. Although AR roles are still far from being completely understood, targeting ARs has been proven to be a valid mean for therapeutic and diagnostic intervention in several diseases, thus prompting scientists to search for new molecules able to modulate, directly or indirectly, AR functions. This Special Issue is aimed at providing the reader with recent advances in the field of ARs as target in human diseases.
Authors are invited to submit original articles dealing with their research in this area of investigation. The proposed topics include, but are not limited to, new AR ligands, AR allosteric modulators or enzyme modulators, designed as chemical probe for the study of adenosine pharmacological role and to highlight the AR-mediated therapeutic effects. Review articles summarizing the current knowledge on adenosine receptors and their ligands will be also of interest.
Prof. Vittoria Colotta
Prof. Daniela Catarzi
Dr. Flavia Varano
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- G protein-coupled receptors
- adenosine receptors
- adenosine receptor ligands
- allosteric modulators
- rational design
- multitarget-directed drugs
- computational studies
- molecular docking